Heron Therapeutics is trading 5.45% up at $0.33, as broader risk-on sentiment supports the move despite no fresh company-specific announcement identified for August 27, 2026.
- The latest material company news remains the August 10 earnings update, which included withdrawn 2026 guidance and uncertainty surrounding CINVANTI patents.
- The S&P 500 is up 0.57% and the Nasdaq Composite is up 1.40%, led by technology and growth stocks.
- The move suggests a global risk-on explanation rather than a new Heron-specific catalyst.